Healthcare Industry News: Sandoz
News Release - January 2, 2008
NPS Pharmaceuticals Appoints Dr. Alan G. Harris Chief Medical Officer
BEDMINSTER, N.J., Jan. 2 (HSMN NewsFeed) -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today the appointment of Alan G. Harris, M.D., Ph.D., as senior vice president and chief medical officer.Francois Nader, M.D., executive vice president and chief operating officer, stated: "Alan brings impressive credentials and industry experience to NPS and will play a critical role in leading the company's research and development programs for GATTEX, PREOS and NPSP156. We welcome his insights and contributions as we focus on obtaining regulatory approvals and expanding the potential indications for these innovative product candidates."
Before joining NPS, Dr. Harris was chief medical officer of Manhattan Pharmaceuticals, therapeutic head of worldwide medical endocrine care at Pfizer, Inc., and vice president of global health research and outcomes at Schering-Plough Corp. where he held a variety of senior medical affairs positions. While at Sandoz (now Novartis), Dr. Harris developed, as project leader, the first long-acting somatostatin analogue, octreotide (Sandostatin ®), for the treatment of gastrointestinal tumors and endocrine diseases.
Dr. Harris currently holds several academic appointments, including adjunct professor in the department of pharmacology at NYU Medical Center in New York, and was previously associate professor of medicine at UCLA Medical School and director of the division of clinical pharmacology in the department of medicine at Cedars-Sinai Medical Center. He has authored over 100 peer-reviewed scientific articles. Dr. Harris is a fellow of the American College of Physicians and a fellow of the Royal College of Physicians (UK).
Dr. Harris received his doctor of medicine degree from the University of Strasbourg, France and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. He undertook post-graduate training in hepatogastroenterology and nutrition from Nice University Medical School, France.
About NPS
NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of January 2, 2008 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended September 30, 2007.
Source: NPS Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
